VOYA Investment Management Portfolio holdings
AUM
$100B
This Quarter Return
+7.39%
1 Year Return
+30.07%
3 Year Return
+120.64%
5 Year Return
+214.86%
10 Year Return
+564.47%
AUM
$96.3B
AUM Growth
+$96.3B
(-0.43%)
Cap. Flow
-$1.83B
Cap. Flow
% of AUM
-1.9%
Top 10 Holdings %
Top 10 Hldgs %
26.4%
Holding
2,875
New
49
Increased
612
Reduced
1,941
Closed
111
Top Buys
Top Sells
| 1 |
Tesla
TSLA
|
$485M |
| 2 |
Apple
AAPL
|
$402M |
| 3 |
Meta Platforms (Facebook)
META
|
$361M |
| 4 |
Marvell Technology
MRVL
|
$285M |
| 5 |
Zscaler
ZS
|
$265M |
Sector Composition
| 1 | Technology | 32.56% |
| 2 | Financials | 9.84% |
| 3 | Consumer Discretionary | 9.4% |
| 4 | Healthcare | 8.11% |
| 5 | Communication Services | 7.06% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
2601
Lyell Immunopharma
LYEL
$213M
| $33.9K | ﹤0.01% | 52,935 -2,604 | -5% | -$1.67K |
|
2602
Editas Medicine
EDIT
$231M
| $33.4K | ﹤0.01% | 26,325 -1,936 | -7% | -$2.46K |
|
2603
Cabaletta Bio
CABA
$133M
| $32.2K | ﹤0.01% | 14,202 -702 | -5% | -$1.59K |
|
2604
Renovaro
RENB
$55M
| $29.5K | ﹤0.01% | +35,312 | New | +$29.5K |
|
2605
Cassava Sciences
SAVA
$110M
| $28.9K | ﹤0.01% | 12,255 -1,007 | -8% | -$2.38K |
|
2606
Lexicon Pharmaceuticals
LXRX
$400M
| $28.4K | ﹤0.01% | 38,418 | – | – |
|
2607
Aemetis
AMTX
$161M
| $28.3K | ﹤0.01% | +10,527 | New | +$28.3K |
|
2608
Veru
VERU
$47.6M
| $27.7K | ﹤0.01% | 42,601 -3,665 | -8% | -$2.38K |
|
2609
Black Diamond Therapeutics
BDTX
$157M
| $26.4K | ﹤0.01% | 12,326 -974 | -7% | -$2.08K |
|
2610
Tenaya Therapeutics
TNYA
$184M
| $26.1K | ﹤0.01% | 18,259 -1,275 | -7% | -$1.82K |
|
2611
Applied Therapeutics
APLT
$71M
| $24.9K | ﹤0.01% | 29,115 -2,758 | -9% | -$2.36K |
|
2612
Pyxis Oncology
PYXS
$79.4M
| $24.8K | ﹤0.01% | 15,897 -1,302 | -8% | -$2.03K |
|
2613
Lineage Cell Therapeutics
LCTX
$267M
| $19.5K | ﹤0.01% | 38,835 -17,951 | -32% | -$9.02K |
|
2614
Precigen
PGEN
$1.34B
| $17K | ﹤0.01% | 15,138 -34,402 | -69% | -$38.5K |
|
2615
Generation Bio
GBIO
$40.4M
| $12.4K | ﹤0.01% | 11,691 -5,510 | -32% | -$5.84K |
|
2616
Stem
STEM
$126M
| $10.3K | ﹤0.01% | 17,143 -44,102 | -72% | -$26.6K |
|
2617
ALX Oncology
ALXO
$62.7M
| – | – | -12,813 | Closed | -$23.3K |
|
2618
A-Mark Precious Metals
AMRK
$576M
| – | – | -5,998 | Closed | -$265K |
|
2619
AnaptysBio
ANAB
$569M
| – | – | -6,602 | Closed | -$221K |
|
2620
Anika Therapeutics
ANIK
$135M
| – | – | -9,960 | Closed | -$246K |
|
|
JBIO
2621
Jade Biosciences, Inc. Common Stock
JBIO
$258M
| – | – | -65,659 | Closed | -$137K |
|
2622
Bar Harbor Bankshares
BHB
$538M
| – | – | -6,586 | Closed | -$203K |
|
|
BLUE
2623
DELISTED
bluebird bio
BLUE
| – | – | -65,897 | Closed | -$34.2K |
|
2624
Bridgewater Bancshares
BWB
$450M
| – | – | -10,231 | Closed | -$145K |
|
2625
Cass Information Systems
CASS
$570M
| – | – | -5,125 | Closed | -$213K |
|